Senti Biosciences Holdings, Inc.
SNTI · XNASCIK 1854270fmd_0XG6F2X4YH5CSVGJQ4WN2B6YJPManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 3 | 4 | 3 | 0 | 0 |
| Rental revenue | – | – | 2 | 7 | – |
| Research and development | 22 | 28 | 32 | 34 | 38 |
| Total operating expenses | 43 | 66 | 95 | 61 | 69 |
| Operating income | (40) | (62) | (93) | (61) | (69) |
| Other non-operating income (expense) | (15) | 12 | 9 | 8 | 7 |
| Income tax expense | – | – | – | 0 | 0 |
| Net income from continuing operations | – | (50) | (83) | (53) | (61) |
| Net income | (55) | (58) | (71) | (53) | (61) |
| Net income to common shareholders | – | – | (71) | (55) | (61) |